Search Results - "VERMEULEN, Wendy"

Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors by PUZANOV, Igor, LEE, Wooin, ROTHENBERG, Mace L, CHEN, Alice P, WADE CALCUTT, M, HACHEY, David L, VERMEULEN, Wendy L, SPANSWICK, Victoria J, LIAO, Chih-Yi, HARTLEY, John A, BERLIN, Jordan D

“…This phase I study assessed the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SJG-136, a…”
Get full text

Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors by RICART, Alejandro D, BERLIN, Jordan D, ROWINSKY, Eric K, ROTHENBERG, Mace L, PAPADOPOULOS, Kyriakos P, SYED, Samira, DROLET, Daniel W, QUARATINO-BAKER, Charlotte, HORAN, Julie, CHICK, Jon, VERMEULEN, Wendy, TOLCHER, Anthony W

“…Purpose: To evaluate the safety and describe the pharmacokinetic profile of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, in combination with…”
Get full text

A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies by Goff, Laura W, Rothenberg, Mace L, Lockhart, A Craig, Roth, Bruce J, VerMeulen, Wendy L, Chan, Emily, Berlin, Jordan D

“…This phase I study was conducted to evaluate the combination of irinotecan, a topoisomerase I inhibitor, with epirubicin, a topoisomerase II inhibitor, when…”
Get full text

Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors by Cardin, Dana Backlund, Park, Haeseong, Diamond, Jennifer Robinson, Drilon, Alexander E., VerMeulen, Wendy L., He, Xiaomin, Hirai, Hiroshi, Soni, Nital, Berlin, Jordan

“…Abstract only 3031 Background: AurA is a key regulator of cell division, including mitotic spindle assembly. However, elevated levels of AurA have been…”
Get full text

A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors by Lockhart, A Craig, Calvo, Emiliano, Tolcher, Anthony W, Rowinsky, Eric K, Shackleton, Gareth, Morrison, J Gilmour, Rafi, Rezvan, VerMeulen, Wendy, Rothenberg, Mace L

“…The thioxanthone analog, SR271425, is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models. The objectives of this phase…”
Get full text